Taysha Gene Therapies Prices Approx. $200 Mln Offering Of Shares And Warrants; Stock Down

Taysha Gene Therapies priced a common stock offering of 32.50 million shares at $6 per share, along with pre-funded warrants for an additional 0.833 million shares. The announcement is primarily a financing update for the clinical-stage biotech company and is modestly dilutive, but the article provides no broader operational or clinical catalyst.

Analysis

Taysha Gene Therapies priced a common stock offering of 32.50 million shares at $6 per share, along with pre-funded warrants for an additional 0.833 million shares. The announcement is primarily a financing update for the clinical-stage biotech company and is modestly dilutive, but the article provides no broader operational or clinical catalyst.